Yttrium (90Y) tacatuzumab tetraxetan explained

Yttrium (90Y) tacatuzumab tetraxetan is an investigational humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.

Notes and References

  1. Web site: Statement On A Nonproprietary Name Adopted By The USAN Council. dead. https://web.archive.org/web/20040911162110/http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium_90_tacatuz.doc. 4 September 2004 . 2004-09-11 .
  2. https://web.archive.org/web/20110705093023/http://apps.who.int/medicinedocs/documents/s14179e/s14179e.pdf WHO Drug Information

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Yttrium (90Y) tacatuzumab tetraxetan".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.